Vancomycin: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>David E. Volk
No edit summary
imported>Robert Badgett
Line 8: Line 8:


==Acute kidney injury==
==Acute kidney injury==
Vancomycin is associated with [[acute kidney injury]] if trough levels are above 15 microg/mL.<ref name="pmid17060545">{{cite journal |author=Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A |title=High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity |journal=Arch. Intern. Med. |volume=166 |issue=19 |pages=2138–44 |year=2006 |pmid=17060545 |doi=10.1001/archinte.166.19.2138}}</ref> To avoid this, the blood levels of vancomycin should be monitored.<ref name="pmid7696720">{{cite journal |author=Welty TE, Copa AK |title=Impact of vancomycin therapeutic drug monitoring on patient care |journal=Ann Pharmacother |volume=28 |issue=12 |pages=1335–9 |year=1994 |pmid=7696720 |doi=}}</ref><ref name="pmid12808304">{{cite journal |author=Iwamoto T, Kagawa Y, Kojima M |title=Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin |journal=Biol. Pharm. Bull. |volume=26 |issue=6 |pages=876–9 |year=2003 |pmid=12808304 |doi=|url=http://www.jstage.jst.go.jp/article/bpb/26/6/876/_pdf}}</ref>
Vancomycin is associated with [[acute kidney injury]] if trough levels are above 15 microg/mL.<ref name="pmid17060545">{{cite journal |author=Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A |title=High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity |journal=Arch. Intern. Med. |volume=166 |issue=19 |pages=2138–44 |year=2006 |pmid=17060545 |doi=10.1001/archinte.166.19.2138}}</ref> To avoid this, the blood levels of vancomycin should be monitored.<ref name="pmid7696720">{{cite journal |author=Welty TE, Copa AK |title=Impact of vancomycin therapeutic drug monitoring on patient care |journal=Ann Pharmacother |volume=28 |issue=12 |pages=1335–9 |year=1994 |pmid=7696720 |doi=}}</ref><ref name="pmid12808304">{{cite journal |author=Iwamoto T, Kagawa Y, Kojima M |title=Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin |journal=Biol. Pharm. Bull. |volume=26 |issue=6 |pages=876–9 |year=2003 |pmid=12808304 |doi=|url=http://www.jstage.jst.go.jp/article/bpb/26/6/876/_pdf}}</ref> Recommended trough levels are 15–20 mg/L.<ref name="pmid19106348">{{cite journal |author=Rybak M, Lomaestro B, Rotschafer JC, ''et al'' |title=Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists |journal=Am J Health Syst Pharm |volume=66 |issue=1 |pages=82–98 |year=2009 |month=January |pmid=19106348 |doi=10.2146/ajhp080434 |url=http://www.ajhp.org/cgi/pmidlookup?view=long&pmid=19106348 |issn=}}</ref>


==References==
==References==

Revision as of 12:16, 28 January 2009

This article is a stub and thus not approved.
 Main Article
 Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
https://en.citizendium.org/wiki/index.php?title=Vancomycin&printable=yes
This editable Main Article is under development and subject to a disclaimer.

Pharmacology

The half life in normal individuals is 4-6 hours.[1]

Adverse effects

Thrombocytopenia

Vancomycin may cause immune thrombocytopenia.[2]

Acute kidney injury

Vancomycin is associated with acute kidney injury if trough levels are above 15 microg/mL.[3] To avoid this, the blood levels of vancomycin should be monitored.[4][5] Recommended trough levels are 15–20 mg/L.[6]

References

  1. ↑ DailyMed. vancomycin hydrochloride (Vancomycin Hydrochloride) injection, solution. Retrieved on 2008-01-06.
  2. ↑ Von Drygalski A, Curtis BR, Bougie DW, et al (2007). "Vancomycin-induced immune thrombocytopenia". N. Engl. J. Med. 356 (9): 904–10. DOI:10.1056/NEJMoa065066. PMID 17329697. Research Blogging.
  3. ↑ Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A (2006). "High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity". Arch. Intern. Med. 166 (19): 2138–44. DOI:10.1001/archinte.166.19.2138. PMID 17060545. Research Blogging.
  4. ↑ Welty TE, Copa AK (1994). "Impact of vancomycin therapeutic drug monitoring on patient care". Ann Pharmacother 28 (12): 1335–9. PMID 7696720. [e]
  5. ↑ Iwamoto T, Kagawa Y, Kojima M (2003). "Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin". Biol. Pharm. Bull. 26 (6): 876–9. PMID 12808304. [e]
  6. ↑ Rybak M, Lomaestro B, Rotschafer JC, et al (January 2009). "Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists". Am J Health Syst Pharm 66 (1): 82–98. DOI:10.2146/ajhp080434. PMID 19106348. Research Blogging.

External links

for injection 3625 - FDA approved drug information (drug label) from DailyMed (U.S. National Library of Medicine).

Retrieved from "https://citizendium.org/wiki/index.php?title=Vancomycin&oldid=373610"